## **Audrey Low**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7162471/publications.pdf

Version: 2024-02-01

7	511	7	7
papers	citations	h-index	g-index
8	8	8	552
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nature Biotechnology, 2019, 37, 640-650.	17.5	205
2	Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. Nucleic Acids Research, 2019, 47, 5465-5479.	14.5	77
3	Efficient Synthesis and Biological Evaluation of 5′-GalNAc Conjugated Antisense Oligonucleotides. Bioconjugate Chemistry, 2015, 26, 1451-1455.	3.6	68
4	Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. Nucleic Acids Research, 2020, 48, 1691-1700.	14.5	63
5	Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides. Nucleic Acids Research, 2021, 49, 9026-9041.	14.5	61
6	Site-specific incorporation of $5\hat{a}\in^2$ -methyl DNA enhances the therapeutic profile of gapmer ASOs. Nucleic Acids Research, 2021, 49, 1828-1839.	14.5	26
7	Evaluation of Phosphorus and Non-Phosphorus Neutral Oligonucleotide Backbones for Enhancing Therapeutic Index of Gapmer Antisense Oligonucleotides. Nucleic Acid Therapeutics, 2022, 32, 40-50.	3.6	10